comparative effectiveness

Research in Review

SBRT Efficacy May Depend on Lung Cancer Histologic Classification

12/28/2016

JCP Editors

Patients with early-stage non-small cell lung cancer (NSCLC) may be more or less responsive to stereotactic body radiation therapy (SBRT) based upon histological classification, according to a study published in the...

...

12/28/2016

Journal of Clinical Pathways

Research in Review

Depression May Cause Decreased Response to Chemotherapy

12/21/2016

JCP Editors

Patients with cancer who are suffering from depression may be less responsive to cancer drugs and less tolerant of their side-effects, a new study shows. ----- Related Content Psychedelic drug psilocybin relieves...

...

12/21/2016

Journal of Clinical Pathways

Research in Review

Chemotherapy Regimens Comparable in Efficacy for Treatment of NSCLC

12/20/2016

JCP Editors

Two of the most common chemotherapy regimens may be comparable in terms of efficacy when used in combination with radiotherapy for treatment of non-small cell lung cancer (NSCLC), according to a recent study...

Two of...

12/20/2016

Journal of Clinical Pathways

Research in Review

Menopausal Symptoms Wrongly Attributed to Tamoxifen Dampen Adherence Rates

12/13/2016

JCP Editors

Menapausal symptoms experienced by women with breast cancer that were wrongly attributed to side effects of tamoxifen treatment had a dampening effect on medication adherence, according to a new...

...

12/13/2016

Journal of Clinical Pathways

News

IBM‚Äôs Watson Agrees With Oncologist Treatment Decisions 90% of the Time

12/12/2016

JCP Editors

IBM’s Watson for Oncology, a computer that helps oncologists make treatment decisions for individual patients, made the same recommendations 90% of the time as a team of specialist oncologists, according to a new...

IBM’s...

12/12/2016

Journal of Clinical Pathways

Research in Review

First-Line Pembrolizumab for NSCLC Improves HRQoL Versus Chemotherapy

12/08/2016

JCP Editors

Patients with early stage metastatic non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 have improved quality of life with pembrolizumab treatment versus standard of care platinum-containing...

...

12/08/2016

Journal of Clinical Pathways

Research in Review

Blood Test Helps Predict Treatment Response for Patients With SCLC

11/29/2016

JCP Editors

Patterns of gene copy number aberrations (CNAs) in isolated small-cell lung cancer (SCLC) cells may help determine how patients will respond to chemotherapy, according to a study published...

...

11/29/2016

Journal of Clinical Pathways

Research in Review

Leukemia Cancer Cells With TP53 Mutations Respond to Mild Chemotherapy

11/28/2016

JCP Editors

Patients with acute myeloid leukemia (AML) whose cells carry TP53 mutations may survive longer if they are treated with decitabine, according to a recent study in The New England Journal of...

...

11/28/2016

Journal of Clinical Pathways

Research in Review

Surgery Better Than Neoadjuvant Chemo for Epithelial Ovarian Cancer

11/23/2016

JCP Editors

Primary cytoreductive surgery (PCS) is better than neoadjuvant chemotherapy (NACT) for overall survival in women aged 70 years or younger with advanced-stage epithelial ovarian cancer (EOC), according to a recent...

...

11/23/2016

Journal of Clinical Pathways

Research in Review

HC-Based Next-Gen Sequencing Aids Treatment Decisions in Lung Cancer

11/23/2016

JCP Editors

Hybrid capture (HC)-based next-generation sequencing (NGS) can identify targetable oncogenic drivers to improve response rates in patients with lung cancer, according to a study published in the Journal of Thoracic...

Hybrid...

11/23/2016

Journal of Clinical Pathways